Business
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following communication with
About this update from Pacira Biosciences, Inc.
[{"type":"image","alt":"Pacira BioSciences","displaySize":"","headline":null,"caption":"Pacira BioSciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/04e0c8f8e2099937e616269a7f79e669"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dRdI2d2CbhpAnNdlbYaSfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/04e0c8f8e2099937e616269a7f79e669","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/dRdI2d2CbhpAnNdlbYaSfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/04e0c8f8e2099937e616269a7f79e669","width":300,"height":300}},"lazy":false},{"type":"text","content":"Clarifies DOMA’s Inaccuracies and the Reality of Pacira’ Efforts to Strengthen its Market Position","length":98,"tagName":"p"},{"type":"text","content":"Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today","length":122,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following communication with important facts stockholders should know to help protect their Pacira investment.","length":370,"tagName":"p"},{"type":"text","content":"The complete text of the letter mailed to stockholders is as follows:","length":69,"tagName":"p"},{"type":"text","content":"May 27, 2026","length":12,"tagName":"p"},{"type":"text","content":"Dear Pacira Stockholders,","length":25,"tagName":"p"},{"type":"text","content":"As we approach our 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 9, 2026, you face an important decision regarding your investment in Pacira.","length":162,"tagName":"p"},{"type":"text","content":"As we’ve communicated with you, one of our stockholders, DOMA Perpetual Capital Management LLC (“DOMA Perpetual” or “DOMA”)1 has continued to pursue a distracting and misinformed proxy contest to replace Pacira’s highly qualified board nominees - Christopher Christie, Samit Hirawat, MD and Thomas Wiggans - with its own candidates, Christopher Dennis, Oliver Benton Curtis III&n...